Friday 28 June – a research day for healthcare professionals organised by the UK Pleural Society and held in London, UK.
Researchers at the Cancer Research UK Southampton Clinical Trials Unit and the University of Leicester are running the NERO trial (Niraparib Efficacy in patients with unResectable MesotheliOma) to test whether a type of drug called a PARP inhibitor could be an...
Working in collaboration with DaSH-Global, a pharmaceutical manufacturing company, we have developed a new digital patient portal known as the ‘Health Companion’. The new system will allow patients to submit data regarding their quality of life and experiences in the...
Mesothelioma UK has launched the Uncovering Mesothelioma report, published by the pharmaceutical company, Bristol Myers Squibb to coincide with Legacy Week (21-28 September). Bristol Myers Squibb invited the charity to collaborate on the report because of its...
If you are a business involved in the management of asbestos or the diseases it causes, why not join our Asbestos Commercial Club (MUKACC) to support the vital work that we do? Joining MUKACC can be a great morale booster for your staff, encouraging them to get...
Mesothelioma UK’s CEO, Liz Darlison, has been confirmed as a speaker at the European Asbestos Forum Conference (EAF). The event will take place from 10-11 November in Amsterdam, in the Netherlands, where she will deliver a talk entitled, Establishing a National...